Dr. Stacie Dusetzina and Dr. Peter Bach present an analysis of the implications of the Trump Administration’s proposed changes to eliminate Medicare Part D rebates from drug manufacturers, published in JAMA.
Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price. Drs. Bach and Mailankody argue that outcomes-based contracts are ill-suited to do so.
Anna Kaltenboeck and Dr. Peter Bach published commentary in Morning Consult, describing key misconceptions surrounding outcomes-based contracting, and what steps are needed to make the approach value-based.